Developer docs
API playgroundTry for free, no card

Search company profiles

CathVision

Full company profile

uuid0000ofy

Namestring
CathVision
Legal namestring
CathVision ApS
Websiteurl
cathvision.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

CathVision is a medical technology company founded in 2013 and headquartered in Copenhagen, Denmark, with a US commercial office in Minnetonka, Minnesota. The company develops the ECGenius System, an electrophysiology (EP) recording platform, together with the CARDIALYTICS AI software suite, targeting the cardiac electrophysiology market and specifically the workflow of catheter ablation for arrhythmias such as atrial fibrillation. Its technical foundation combines a proprietary low-noise hardware amplifier with machine-learning software modules; the company holds 13 patent families and has secured FDA 510(k) clearance for the ECGenius System (May 2022), FDA clearance for its PVI Analyzer and Signal Complexity AI algorithms (August 2023), and CE Mark (February 2025). The platform is designed to integrate with hospital EP lab infrastructure, including third-party 3D mapping systems and EMR platforms (EMR integration announced December 2024).\n\nCathVision's business model is enterprise capital equipment sales of the ECGenius recording system into hospital EP laboratories, supplemented by per-module software revenue from AI applications such as the PVI Analyzer, PFAnalyzer, Entrainment Assistant, FaST Algorithm, and CSP Assistant. Go-to-market has progressed from limited market release to commercial expansion, anchored by placements at elite US academic medical centers including Cleveland Clinic, Johns Hopkins, Houston Methodist, NYU Langone, IU Health, Valley Health, and University of Vermont, with initial European footprint at OLV Hospital Aalst in Belgium following CE Mark. The company operates with 11–50 employees, has built an R&D organization of 20+ engineers under VP Engineering Allan Gersfelt-Larsen, and has raised approximately $30M across multiple funding rounds between 2017 and 2023.

Short descriptiontext

CathVision is a medical technology company developing the ECGenius electrophysiology recording system and CARDIALYTICS AI suite for cardiac ablation procedures, sold to hospital electrophysiology labs and electrophysiologists treating arrhythmias.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCopenhagen, Denmark
HQ citystring
Copenhagen
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
electrophysiology recording systems, cardiac ablation analytics, AI electrophysiology software, cardiac medical devices, EP signal processing
Industry3 codes
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAC
Electrophysiology (Heart Rhythm)
SECONDARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cardiac Electrophysiology Recording Systems
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1ECGenius System Hardware
TypeHardware Sales
Description

Sale of proprietary EP recording system hardware including the amplifier and software platform. FDA-cleared for commercial sale in the United States with CE Mark for European market.

cathvision.com
2AI Algorithm Licensing (Price-per-use)
TypeUsage Based
Description

CARDIALYTICS algorithms (PVI Analyzer, Signal Complexity) available to ECGenius System users on a price-per-use basis. Provides recurring usage-based revenue from existing installed base.

cathvision.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
Pricing details1 tier
1AI Analytics (PVI Analyzer, Signal Complexity) available as add-on modules
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Available to physicians using the ECGenius System on a price-per-use basis

cathvision.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1CARDIALYTICS
Description

Suite of AI-powered analytics including PVI Analyzer, Signal Complexity, PFAnalyzer, FaST Algorithm, Entrainment Assistant, and CSP Assistant for electrophysiology procedures

cathvision.com
+6 more records
Core offering1 text field

CathVision develops and commercializes the ECGenius System, an FDA-cleared electrophysiology (EP) recording platform with a proprietary low-noise hardware amplifier that acquires high-fidelity cardiac electrograms for ablation procedures. The company also sells the CARDIALYTICS AI analytics suite, which provides automated electrogram interpretation modules (including FDA-cleared PVI Analyzer and Signal Complexity algorithms) on a price-per-use basis to existing ECGenius users for the diagnosis and treatment of complex cardiac arrhythmias.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • First and only EP recording system with AI algorithm to measure success of cardiac ablation (FDA cleared August 2023)
+2 more records
Product overview1 text field

CathVision offers the ECGenius System as its core hardware platform—a proprietary EP recording system that acquired FDA clearance in May 2022 and CE Mark in February 2025 for high-fidelity cardiac signal acquisition. The system integrates with the CARDIALYTICS AI analytics suite, which includes FDA-cleared modules (PVI Analyzer, Signal Complexity) and investigational modules (PFAnalyzer, FaST Algorithm, Entrainment Assistant, CSP Assistant). The ECGenius hardware serves as the foundation for AI-powered electrogram analysis, with algorithms available on a price-per-use basis.

Product and service2 records
1ECGenius System
CategoryEP Recording Hardware
Description

The ECGenius System is an FDA-cleared electrophysiology (EP) recording platform featuring a proprietary hardware amplifier that acquires high-fidelity, low-noise cardiac electrograms. It includes 12-lead ECG, 128 intracardiac channels, and 4 blood pressure channels to help electrophysiologists diagnose and treat complex cardiac arrhythmias. CE Mark received February 2025 for European distribution.

2CARDIALYTICS AI Analytics Suite
CategoryAI Analytics Software
Description

CARDIALYTICS is CathVision's AI-powered analytics platform comprising multiple algorithmic modules (PVI Analyzer, Signal Complexity, PFAnalyzer, FaST Algorithm, Entrainment Assistant, CSP Assistant) that integrate with the ECGenius System to provide automated electrogram analysis during cardiac ablation procedures. Modules are available to ECGenius users on a price-per-use basis.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

First US clinical trial site evaluating ECGenius System safety and technical performance. Conducted comparative benchmarking of electrogram signal quality against commercial systems.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical study site evaluating Signal Complexity algorithm for persistent AF treatment. 28+ patients enrolled. Dr. Larry Chinitz serves as clinical advisor and key opinion leader.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

European clinical site for persistent AF study led by Dr. Tom De Potter. Evaluating Signal Complexity algorithm for ablation therapy impact analysis.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

European multicenter clinical sites for PVISION study (90 patients across 4 sites in Belgium and France) evaluating PVI Analyzer algorithm for automated pulmonary vein isolation assessment.

5HeartX Cardiovascular Accelerator
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Selected for 2025 HeartX Cardiovascular Accelerator program focused on innovative cardiovascular healthcare solutions.

medaxiom.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborated on Pulsed Field Ablation research with PFAnalyzer module. Study confirmed reliability of unipolar voltage thresholds for distinguishing tissue states post-PFA.

7University Hospital of Split
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical collaborator on PFAnalyzer research letter published in Heart Rhythm journal. Demonstrated clinical feasibility of electrogram analysis tool for lesion assessment in PFA.

cathvision.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Acutus Medical
TypeEmerging player
Description

A US-based EP mapping and ablation company offering the AcQMap system with proprietary non-contact mapping. Acutus is a comparable emerging competitor targeting advanced ablation workflows similar to CathVision's high-fidelity EP positioning.

2Abbott
TypeDirect peer
Description

Through its acquisition of St. Jude Medical, Abbott offers the CardioLab EP recording system and EnSite X mapping platform, making it a direct competitor in hospital EP labs alongside CathVision's ECGenius and CARDIALYTICS offerings.

TypeDirect peer
Description

A leading cardiovascular medtech major that competes directly with CathVision in EP recording (LabSystem Pro) and ablation, while also offering integrated mapping systems and ablation catheters. Boston Scientific is the most direct incumbent competitor and reference customer replacement target.

TypeBroad incumbent
Description

A large incumbent in cardiac imaging, cath lab, and EP-adjacent technologies. While not a direct EP recording rival in the same narrow category, Siemens competes for hospital cardiology capex budgets and increasingly offers digital and AI features overlapping with CARDIALYTICS.

TypeBroad incumbent
Description

A broad incumbent in cardiac care including EP lab integration, imaging, and patient monitoring. While Philips does not focus specifically on standalone EP recording, it competes for hospital cardiology budgets and has historically offered EP-adjacent capital equipment.

TypeEmerging player
Description

Pioneer in robotic EP navigation; its Genesis and Niobe systems are used in complex ablation procedures alongside conventional recording and mapping. Stereotaxis overlaps with CathVision at the high-complexity end of the EP lab market.

7Biosense Webster (Johnson & Johnson)
TypeDirect peer
Description

The market-leading EP franchise within J&J, offering the CARTO 3D mapping system and a broad ablation catheter portfolio. Biosense Webster is the dominant EP ecosystem player CathVision must position against for procedure-level data and analytics.

TypeDirect peer
Description

Provides the Mac-Lab and CardioLab hemodynamic and EP recording systems widely used in cardiac catheterization and EP labs. GE HealthCare competes head-to-head with ECGenius in EP recording and benefits from broad hospital relationships.

9MicroPort Scientific (Cardiac Rhythm Management / EP)
TypeRegional player
Description

A global medical device group with growing EP and cardiac ablation offerings, particularly strong in Asia and Europe. MicroPort is a comparable competitor in EP equipment commercialization, though its primary geographic strengths differ from CathVision's US-anchored base.

TypeEmerging player
Description

A French AI-focused EP medtech whose VX1 software provides AI decision support for atrial fibrillation ablation. Volta is one of the closest comparables to CathVision's CARDIALYTICS AI analytics strategy and targets the same electrophysiologist users.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CathVision

Cardiac Electrophysiology Recording Systemscathvision.com

CathVision is a medical technology company developing the ECGenius electrophysiology recording system and CARDIALYTICS AI suite for cardiac ablation procedures, sold to hospital electrophysiology labs and electrophysiologists treating arrhythmias.

What CathVision does

CathVision is a medical technology company founded in 2013 and headquartered in Copenhagen, Denmark, with a US commercial office in Minnetonka, Minnesota. The company develops the ECGenius System, an electrophysiology (EP) recording platform, together with the CARDIALYTICS AI software suite, targeting the cardiac electrophysiology market and specifically the workflow of catheter ablation for arrhythmias such as atrial fibrillation. Its technical foundation combines a proprietary low-noise hardware amplifier with machine-learning software modules; the company holds 13 patent families and has secured FDA 510(k) clearance for the ECGenius System (May 2022), FDA clearance for its PVI Analyzer and Signal Complexity AI algorithms (August 2023), and CE Mark (February 2025). The platform is designed to integrate with hospital EP lab infrastructure, including third-party 3D mapping systems and EMR platforms (EMR integration announced December 2024).\n\nCathVision's business model is enterprise capital equipment sales of the ECGenius recording system into hospital EP laboratories, supplemented by per-module software revenue from AI applications such as the PVI Analyzer, PFAnalyzer, Entrainment Assistant, FaST Algorithm, and CSP Assistant. Go-to-market has progressed from limited market release to commercial expansion, anchored by placements at elite US academic medical centers including Cleveland Clinic, Johns Hopkins, Houston Methodist, NYU Langone, IU Health, Valley Health, and University of Vermont, with initial European footprint at OLV Hospital Aalst in Belgium following CE Mark. The company operates with 11–50 employees, has built an R&D organization of 20+ engineers under VP Engineering Allan Gersfelt-Larsen, and has raised approximately $30M across multiple funding rounds between 2017 and 2023.

CathVision firmographics

Firmographics
Name
CathVision
Legal name
CathVision ApS
Website
https://cathvision.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
CathVision is a medical technology company developing the ECGenius electrophysiology recording system and CARDIALYTICS AI suite for cardiac ablation procedures, sold to hospital electrophysiology labs and electrophysiologists treating arrhythmias.
Ownership category
akta.pro rank

CathVision industry classification

Industry
Product category
Cardiac Electrophysiology Recording Systems
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAC
Electrophysiology (Heart Rhythm)
SECONDARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Electrophysiology recording systems
  • Cardiac ablation analytics
  • AI electrophysiology software
  • Cardiac medical devices
  • EP signal processing

Where CathVision is headquartered

Location

Headquarters

HQ city
Copenhagen
HQ country
Denmark
HQ region
Europe

Offices2 records

Markets served

CathVision business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. ECGenius System Hardware: Sale of proprietary EP recording system hardware including the amplifier and software platform. FDA-cleared for commercial sale in the United States with CE Mark for European market.
  2. AI Algorithm Licensing (Price-per-use): CARDIALYTICS algorithms (PVI Analyzer, Signal Complexity) available to ECGenius System users on a price-per-use basis. Provides recurring usage-based revenue from existing installed base.

Pricing tiers

ModelBillingPrice
Usage-basedPay-as-you-goAI Analytics (PVI Analyzer, Signal Complexity) available as add-on modules

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

CathVision product offering

Product offering

Core offering

CathVision develops and commercializes the ECGenius System, an FDA-cleared electrophysiology (EP) recording platform with a proprietary low-noise hardware amplifier that acquires high-fidelity cardiac electrograms for ablation procedures. The company also sells the CARDIALYTICS AI analytics suite, which provides automated electrogram interpretation modules (including FDA-cleared PVI Analyzer and Signal Complexity algorithms) on a price-per-use basis to existing ECGenius users for the diagnosis and treatment of complex cardiac arrhythmias.

Product overview

CathVision offers the ECGenius System as its core hardware platform—a proprietary EP recording system that acquired FDA clearance in May 2022 and CE Mark in February 2025 for high-fidelity cardiac signal acquisition. The system integrates with the CARDIALYTICS AI analytics suite, which includes FDA-cleared modules (PVI Analyzer, Signal Complexity) and investigational modules (PFAnalyzer, FaST Algorithm, Entrainment Assistant, CSP Assistant). The ECGenius hardware serves as the foundation for AI-powered electrogram analysis, with algorithms available on a price-per-use basis.

Differentiator

Problem solved

Functional benefit

Brands

  • CARDIALYTICS: Suite of AI-powered analytics including PVI Analyzer, Signal Complexity, PFAnalyzer, FaST Algorithm, Entrainment Assistant, and CSP Assistant for electrophysiology procedures
  • ECGenius System
  • PFAnalyzer
  • Signal Complexity
  • PVI Analyzer
  • FaST Algorithm
  • Entrainment Assistant

Products and services

  • ECGenius System The ECGenius System is an FDA-cleared electrophysiology (EP) recording platform featuring a proprietary hardware amplifier that acquires high-fidelity, low-noise cardiac electrograms. It includes 12-lead ECG, 128 intracardiac channels, and 4 blood pressure channels to help electrophysiologists diagnose and treat complex cardiac arrhythmias. CE Mark received February 2025 for European distribution.
  • CARDIALYTICS AI Analytics Suite CARDIALYTICS is CathVision's AI-powered analytics platform comprising multiple algorithmic modules (PVI Analyzer, Signal Complexity, PFAnalyzer, FaST Algorithm, Entrainment Assistant, CSP Assistant) that integrate with the ECGenius System to provide automated electrogram analysis during cardiac ablation procedures. Modules are available to ECGenius users on a price-per-use basis.

Quantifiable outcome

  • First and only EP recording system with AI algorithm to measure success of cardiac ablation (FDA cleared August 2023)
  • +2 more outcomes

Companies that use CathVision

Customer profile

Named customers7 records

Segments2 records

Ideal customer profiles2 records

CathVision technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability6 records

Feature6 records

CathVision partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • University of Vermont Medical CentercoreStrategic or Co-development PartnerFirst US clinical trial site evaluating ECGenius System safety and technical performance. Conducted comparative benchmarking of electrogram signal quality against commercial systems.
  • NYU Langone HealthcoreStrategic or Co-development PartnerClinical study site evaluating Signal Complexity algorithm for persistent AF treatment. 28+ patients enrolled. Dr. Larry Chinitz serves as clinical advisor and key opinion leader.
  • OLV Hospital AalstcoreStrategic or Co-development PartnerEuropean clinical site for persistent AF study led by Dr. Tom De Potter. Evaluating Signal Complexity algorithm for ablation therapy impact analysis.
  • AZ Sint-Jan Brugge-Oostende, UZ Gent, UZ Brussels, Clinique Pasteur ToulousecoreStrategic or Co-development PartnerEuropean multicenter clinical sites for PVISION study (90 patients across 4 sites in Belgium and France) evaluating PVI Analyzer algorithm for automated pulmonary vein isolation assessment.
  • HeartX Cardiovascular AcceleratorminorStrategic or Co-development PartnerSelected for 2025 HeartX Cardiovascular Accelerator program focused on innovative cardiovascular healthcare solutions.
  • Mount SinaicoreStrategic or Co-development PartnerCollaborated on Pulsed Field Ablation research with PFAnalyzer module. Study confirmed reliability of unipolar voltage thresholds for distinguishing tissue states post-PFA.
  • University Hospital of SplitcoreStrategic or Co-development PartnerClinical collaborator on PFAnalyzer research letter published in Heart Rhythm journal. Demonstrated clinical feasibility of electrogram analysis tool for lesion assessment in PFA.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

CathVision competitors and assessment

Company assessment

Emerging players

  • Acutus Medical: A US-based EP mapping and ablation company offering the AcQMap system with proprietary non-contact mapping. Acutus is a comparable emerging competitor targeting advanced ablation workflows similar to CathVision's high-fidelity EP positioning.
  • Stereotaxis: Pioneer in robotic EP navigation; its Genesis and Niobe systems are used in complex ablation procedures alongside conventional recording and mapping. Stereotaxis overlaps with CathVision at the high-complexity end of the EP lab market.
  • Volta Medical: A French AI-focused EP medtech whose VX1 software provides AI decision support for atrial fibrillation ablation. Volta is one of the closest comparables to CathVision's CARDIALYTICS AI analytics strategy and targets the same electrophysiologist users.

Direct peers

  • Abbott: Through its acquisition of St. Jude Medical, Abbott offers the CardioLab EP recording system and EnSite X mapping platform, making it a direct competitor in hospital EP labs alongside CathVision's ECGenius and CARDIALYTICS offerings.
  • Boston Scientific: A leading cardiovascular medtech major that competes directly with CathVision in EP recording (LabSystem Pro) and ablation, while also offering integrated mapping systems and ablation catheters. Boston Scientific is the most direct incumbent competitor and reference customer replacement target.
  • Biosense Webster (Johnson & Johnson): The market-leading EP franchise within J&J, offering the CARTO 3D mapping system and a broad ablation catheter portfolio. Biosense Webster is the dominant EP ecosystem player CathVision must position against for procedure-level data and analytics.
  • GE HealthCare: Provides the Mac-Lab and CardioLab hemodynamic and EP recording systems widely used in cardiac catheterization and EP labs. GE HealthCare competes head-to-head with ECGenius in EP recording and benefits from broad hospital relationships.

Broad incumbents

  • Siemens Healthineers: A large incumbent in cardiac imaging, cath lab, and EP-adjacent technologies. While not a direct EP recording rival in the same narrow category, Siemens competes for hospital cardiology capex budgets and increasingly offers digital and AI features overlapping with CARDIALYTICS.
  • Philips: A broad incumbent in cardiac care including EP lab integration, imaging, and patient monitoring. While Philips does not focus specifically on standalone EP recording, it competes for hospital cardiology budgets and has historically offered EP-adjacent capital equipment.

Regional players

  • MicroPort Scientific (Cardiac Rhythm Management / EP): A global medical device group with growing EP and cardiac ablation offerings, particularly strong in Asia and Europe. MicroPort is a comparable competitor in EP equipment commercialization, though its primary geographic strengths differ from CathVision's US-anchored base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

CathVision social profiles

Digital presence

CathVision compliance and trust

Trust signal

Compliance3 records

CathVision financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CathVision leadership team

Management profile

Number of profiles

Profiles9 records

CathVision funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CathVision M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CathVision

What does CathVision do?

CathVision develops and commercializes the ECGenius System, an FDA-cleared electrophysiology (EP) recording platform with a proprietary low-noise hardware amplifier that acquires high-fidelity cardiac electrograms for ablation procedures. The company also sells the CARDIALYTICS AI analytics suite, which provides automated electrogram interpretation modules (including FDA-cleared PVI Analyzer and Signal Complexity algorithms) on a price-per-use basis to existing ECGenius users for the diagnosis and treatment of complex cardiac arrhythmias.

Is CathVision a public or private company?

CathVision is a private company. It is classified as venture growth investor backed and is currently operating.

When was CathVision founded?

CathVision was founded in 2013. It employs 11 to 50 people.

Where is CathVision based?

CathVision is headquartered in Copenhagen, Denmark, in the Europe region.

How does CathVision make money?

Two revenue lines are on record. ECGenius System Hardware is the primary driver. The others are AI Algorithm Licensing (Price-per-use).

Who are CathVision's main competitors?

Emerging players on record are Acutus Medical, Stereotaxis and Volta Medical. Direct peers are Abbott, Boston Scientific, Biosense Webster (Johnson & Johnson) and GE HealthCare. Broad incumbents are Siemens Healthineers and Philips. MicroPort Scientific (Cardiac Rhythm Management / EP) is listed as a regional player.

Does CathVision have an API?

No public API is recorded for CathVision.

What industry is CathVision in?

CathVision's product category is Cardiac Electrophysiology Recording Systems. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems, with a secondary code of HLAKABAC, Electrophysiology (Heart Rhythm). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCathVision Demonstrates Clinical Progress in Pulsed Field Ablation With PFAnalyzer - Advancing Lesion Assessment and Restoring Electrogram-Driven ElectrophysiologyCathVision announced significant clinical progress in Pulsed Field Ablation with its PFAnalyzer™ software module, including a research letter published in the Heart Rhythm journal. A study conducted at University Hospital of Split in collaboration with Mount Sinai confirmed that low-amplitude unipolar voltage thresholds (~0.1 mV) can reliably distinguish between electrically silent tissue and residual activity following PFA. The findings demonstrate the feasibility of real-time unipolar electrogram analysis during PFA procedures, potentially addressing the growing gap between energy delivery and electrophysiologic feedback in catheter ablation workflows.PR NewswireCathVision Announces Appointment of Eric Thepaut as Independent Chairman of the Board and Releases ECGenius® System Version 3.5CathVision, a Copenhagen-based medical technology company specializing in cardiac electrophysiology recording technology, announced the appointment of Eric Thepaut as Independent Chairman of the Board, following his recent retirement from Boston Scientific Corporation where he served as President, EMEA. The company also released Version 3.5 of its ECGenius® Software, featuring user interface improvements, IT integration capabilities including DICOM archiving, hardware refinements to reduce post-pacing artifacts, and streamlined 12-lead ECG capture workflows. With ECGenius and Cardialytics FDA-cleared in 2023 and ECGenius CE-marked in 2025, CathVision is now preparing to expand its commercial footprint in the United States and Europe.PR NewswireCathVision to Showcase Innovations at AF Symposium, Present New ScienceCathVision announced its participation in the AF Symposium 2025 in Boston, where it will showcase its ECGenius System for electrophysiology procedures. The company presented new research on atrial tachycardia entrainment software developed in collaboration with NYU Langone Health, demonstrating technology that automates measurements and aims to enhance physician decision-making in complex ablation cases. The research highlights CathVision's ongoing commitment to advancing cardiac signal analysis and ablation targeting tools.PR NewswireCathVision to Highlight Post PFA Energy Calculation Measurement Method at HRS 2024CathVision, a Denmark-based medical technology company, will showcase its new post-pulsed field ablation (PFA) residual energy calculation method PFAnalyzer™ along with the AI-powered ECGenius System at Heart Rhythm 2024 in Boston from May 16-19. The company developed PFAnalyzer to address a gap identified in pivotal trials showing that acute PFA techniques do not predict durable ablation outcomes, providing an objective in-procedure measurement marker for procedure success. CathVision's ECGenius System, with its low-noise floor and Predictive Filter technology, enables the residual energy calculation technique and leverages CARDIALYTICS AI algorithms for automated electrogram analysis.PR NewswireCathVision to Present Predictive Filtering Capabilities of ECGenius System at EHRA 2024CathVision announced data from the PVISION trial demonstrating that the ECGenius System's predictive noise filter significantly increases the time window before noise saturates pulmonary vein (PV) potentials during PVI procedures. The trial analyzed 68 veins from 24 patients, showing the filter increased mean time to artifact from 69 seconds to 82 seconds (P < 0.001), with paired analysis revealing noise exceeding PV amplitude was reduced from 116 seconds to 26 seconds. The data will be presented in a poster at EHRA 2024, with Prof. Dr. Jan De Pooter from Ghent University highlighting that the filter eliminates noise from electrogram data during cryo ablation procedures.PR NewswireCathVision CEO Mads Matthiesen to Present at LSI EuropeMads Matthiesen, CEO of CathVision, is set to present at the LSI Europe Emerging Medtech Summit on September 21 in Barcelona, discussing the company's electrophysiology solutions. His presentation will cover innovative products like the ECGenius System and CARDIALYTICS, along with opportunities for commercial adoption and investment. This event brings together innovators and investors in the healthcare sector.PR NewswireCathVision Secures FDA Clearance of First & Only EP Recording System with AI Algorithm to Measure Success of Cardiac AblationCathVision, a medical technology company headquartered in Denmark, announced FDA clearance and commercial availability of its ECGenius System with CARDIALYTICS AI algorithms, making it the first and only electrophysiology recording system with AI capabilities to measure cardiac ablation outcomes. The system provides automated electrogram interpretation and PVI isolation confirmation for treating complex atrial arrhythmias including atrial fibrillation. The company, which also maintains a US office in Minnesota, positions this clearance as a milestone in its mission to enhance clinical decision-making in the EP lab.FinSMEsCathVision Raises $9M in FundingCathVision, a medical technology company based in Copenhagen, raised $9 million in funding, bringing its total capital to $30 million. The company plans to utilize these funds to expand its U.S. presence, grow its sales team, and further develop its AI-powered CARDIALYTICS suite alongside its ECGenius System.PR NewswireCathVision Secures $9 Million in Funding to Accelerate Adoption of ECGenius System & CARDIALYTICS AI-SuiteCathVision announced a $9 million financing round to accelerate the commercial adoption of its ECGenius System and expand its U.S. presence. The funding will support sales team expansion and further development of the CARDIALYTICS AI-suite for electrophysiology procedures. This brings the company's total raised capital to nearly $30 million since its inception.